Company
Valion Bio, Inc.
Valion Bio (Nasdaq: VBIO) is a clinical-stage immunotherapeutics company developing Entolimod™, a first-in-class TLR5 agonist licensed for the treatment of Acute Radiation Syndrome (ARS) via the FDA Animal Rule pathway — a regulatory framework that positions the program for approval without traditional efficacy trials in humans. The company also advances Entolasta™, a next-generation immunologically optimized variant engineered for chronic therapeutic applications including oncology supportive care and longevity. Entolimod™ addresses one of the most underserved markets in national security — the protection of warfighters, first responders, and civilian populations from radiation exposure — with inbound interest from BARDA, NIAID, and the Department of War. The program differentiates meaningfully from stockpiled G-CSF agents through its multi-system mechanism of action and administration flexibility. Valion Bio's wholly owned subsidiary, Velocity Bioworks (San Antonio, TX), is a full-service CDMO providing domestic biomanufacturing infrastructure that simultaneously advances the company's own pipeline with reduced cost, eliminated outsourcing delays, and direct quality oversight.
Valion Bio, Inc. is a publicly traded company. It trades under the ticker VBIO. Leadership tracked by CEOInsider includes Lisa Wolf (CEO).
Leadership
Current
Recent developments
AI summary of recent coverageRecent coverage of Valion Bio has focused on significant management and board restructuring, including the expansion of Lisa Wolf's role to president and COO alongside the addition of two new board directors. The company has also announced a Series B/C funding round raising $7.74 million and executed a reverse stock split, while pursuing research initiatives including a planned mouse study related to radiation exposure.
Summarized from the headlines in the sidebar; see each source for the full story.